interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Cytarabine; Daunorubicin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Cytarabine; Daunorubicin, and who makes it?

Cytarabine; Daunorubicin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Cytarabine; Daunorubicin1 dosage-form group in the Orange Book
0generic makers listed
  1. Cytarabine; Daunorubicin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Vyxeos. No generic is listed as marketed.

2015202020252030203501brand 2017data datePatent 7850990 listed to expire 23 January 2027Patent 9271931 listed to expire 23 January 2027Patent 7850990*PED listed to expire 23 July 2027Patent 9271931*PED listed to expire 23 July 2027Patent 8022279 listed to expire 14 September 2027Patent 8022279*PED listed to expire 14 March 2028Patent 8092828 listed to expire 1 April 2029Patent 8092828*PED listed to expire 1 October 2029Patent 10835492 listed to expire 15 October 2032Patent 10028912 listed to expire 15 October 2032Patent 10166184 listed to expire 15 October 2032Patent 10028912*PED listed to expire 15 April 2033Patent 10835492*PED listed to expire 15 April 2033Patent 10166184*PED listed to expire 15 April 2033Exclusivity ODE-350 to 30 March 2028Exclusivity PED to 30 September 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 March 2028Exclusivity ODE-350 Vyxeos
  • 30 September 2028Exclusivity PED Vyxeos
  • 23 January 2027Patent 7850990 drug product
  • 23 January 2027Patent 9271931 drug product
  • 23 July 2027Patent 7850990*PED
  • 23 July 2027Patent 9271931*PED
  • 14 September 2027Patent 8022279 drug product
  • 14 March 2028Patent 8022279*PED
  • 1 April 2029Patent 8092828
  • 1 October 2029Patent 8092828*PED

6 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.